GlassScriptPhysician profile
Tamika Spady
NPI 1982145165
$2,517.28
in general payments reported to CMS, 2019-2025
13 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $774 · 2023: $246 · 2024: $783 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $862.86 | 2021-2025 | Fasenra, Breztri |
| Glaxosmithkline, LLC. | $499.80 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $403.88 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.83 | 2021-2024 | Aralast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.99 | 2021-2025 | Ofev |
| Baxter Healthcare | $138.17 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $132.08 | 2021-2022 | |
| Electromed, INC. | $50.14 | 2021-2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $46.15 | 2021-2022 | |
| Abbvie INC. | $24.72 | 2022 | |
| United Therapeutics Corporation | $24.48 | 2024 | Tyvaso |
| La Jolla Pharmaceutical Company | $22.34 | 2024 | Giapreza |
| Philips North America LLC | $13.84 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamika Spady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.